Young Plasma Infusion and Parabiosis-Derived Therapies
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
Human benefit rests only on small mechanistic/feasibility studies (e.g., PMC 2024 perioperative trial, NCT04241159 safety study); no RCT has shown a longevity or anti-aging benefit, and the FDA has stated there is no proven clinical benefit.
Reference only. Not medical advice.
Young plasma infusion is the practice of transfusing blood plasma from young donors into older recipients, marketed with claims of reversing aging, dementia, or various chronic diseases. The concept traces to heterochronic parabiosis experiments in mice, where surgically joining a young and an old animal's circulation produced improvements in some aging markers in the older animal, and separate experiments in which young mouse plasma alone was infused into old mice. These rodent findings generated substantial scientific interest in identifying specific 'young blood factors,' such as GDF11, though follow-up work has been mixed and some early positive findings have not reproduced consistently. Human evidence is sparse. A small randomized trial examined young donor plasma components in older surgical patients and found changes in inflammatory and immune markers after tissue injury, but this measured short-term perioperative biology, not aging or longevity outcomes. A registered feasibility study (ClinicalTrials.gov NCT04241159) examined safety of allogeneic young plasma infusion in older adults, again as a feasibility and safety study rather than a demonstration of anti-aging benefit. No randomized controlled trial has shown that young plasma slows aging, extends lifespan, or reverses age-related disease in humans. The FDA has explicitly and repeatedly warned that there is no proven clinical benefit of young donor plasma for preventing aging or treating conditions such as dementia, Parkinson's disease, or Alzheimer's disease, and has flagged real risks including allergic reactions, circulatory overload, transfusion-related lung injury, and infectious disease transmission. Despite this, plasma infusions continue to be marketed at some private longevity clinics, generally outside conventional medical guidelines and without insurance coverage, at costs that can run into the thousands of dollars per session. This intervention sits firmly in the experimental, largely unproven category, with regulatory bodies actively discouraging its off-label commercial use.
Young plasma infusion is the practice of transfusing blood plasma from young donors into older recipients, marketed with claims of reversing aging, dementia, or various chronic diseases.
Safety in detail
The FDA warns of allergic reactions, circulatory overload, transfusion-related lung injury, and infectious disease transmission risk from plasma infusions marketed for anti-aging purposes, which it has not approved for this use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Parabiosis, surgically joining the circulatory systems of two animals, dates to 19th century physiology experiments and was revived in the 2000s by Stanford researchers including Thomas Rando, Irina Conboy, and Saul Villeda, whose studies found that blood or plasma from young mice could improve markers of muscle repair, liver regeneration, and cognition in old mice. This preclinical excitement led to a wave of for-profit clinics in the 2010s, notably Ambrosia, offering young donor plasma infusions directly to paying consumers without human trials establishing benefit. The FDA issued a public safety warning in February 2019 and reissued it in December 2024, and Ambrosia closed shortly after the first warning, though similar offerings have persisted at other clinics.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Young Plasma Infusion and Parabiosis-Derived Therapies. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.